TP53 and adenocarcinoma: In this review, we summarized clinical and pathological characteristics of NE/SC and reviewed molecular events underlying transition from adenocarcinoma to NE/SC with a special focus on key drivers including inactivation of TP53/RB1 and other drivers emerging upon androgen withdrawal.